Agenus' BOT+BAL Combination Shows Durable Responses in Checkpoint-Refractory Melanoma
Event summary
- Agenus presented Phase 2 data from the C-800-23 study at ASCO 2026, showing durable responses and meaningful survival in advanced checkpoint-refractory melanoma patients.
- The BOT+BAL combination achieved a median overall survival of 16.6 months and a 22% confirmed objective response rate in 36 heavily pretreated patients.
- In the subgroup of patients refractory to both prior anti-PD-(L)1 and anti-CTLA-4 therapy, median overall survival was not reached, with 64% of patients alive at two years.
- The data will be presented by Dr. Michael Atkins on May 31, 2026, at the ASCO Annual Meeting in Chicago.
- Safety findings were consistent with known profiles of CTLA-4 and PD-1 checkpoint inhibition, with no new safety signals observed.
The big picture
Agenus' Phase 2 data for BOT+BAL in checkpoint-refractory melanoma underscores the ongoing quest for effective treatments in immuno-oncology. The results highlight the potential of mechanistically differentiated CTLA-4-based combinations to address unmet needs in patients who have exhausted standard checkpoint therapies. This development comes amid broader industry efforts to extend the benefits of immunotherapy to historically resistant tumor types, positioning Agenus as a key player in the evolving immuno-oncology landscape.
What we're watching
- Clinical Validation
- Whether the durable responses and survival outcomes observed in the Phase 2 study will translate into regulatory approvals and market adoption.
- Competitive Positioning
- How Agenus' BOT+BAL combination will differentiate itself in the crowded immuno-oncology space, particularly for checkpoint-refractory patients.
- Pipeline Progression
- The pace at which Agenus advances BOT+BAL into later-stage trials and potential approvals across other difficult-to-treat solid tumors.
Related topics